MAPT and Alzheimer disease: In the new diagnostic framework for preclinical Alzheimer’s disease, comprising biomarker-based research criteria developed by the workgroups of the National Institute on Aging–Alzheimer’s Association (NIA-AA) and those proposed by the International Working Group (IWG-2), the availability of label-free, real-time and low-cost methods based on biosensing tau biomarker in CSF represents an important possibility.